title: Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy.
abstract: Liver cirrhosis patients generally progress to liver failure. To cure this progressive disease, we developed a novel cell therapy using bone marrow cells; autologous bone marrow cell infusion (ABMi) therapy. We previously described the possible action mechanism of ABMi therapy in the cirrhotic liver, and showed the timeline and results of clinical studies of ABMi therapy. We have also carried out other clinical studies using bone marrow cells and granulocyte colony-stimulating factor. Here, we report a new randomized clinical trial to evaluate the effects of ABMi therapy. However, ABMi therapy may not be possible in patients who are unable to undergo general anesthesia; therefore, we have started to develop a next-generation stem cell therapy using cultured mesenchymal stem cells.
authors.affiliation: Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi, 755-8505, Japan. terais@yamaguchi-u.ac.jp
authors.forename: Shuji
authors.initials: S
authors.lastname: Terai
authors.forename: Haruko
authors.initials: H
authors.lastname: Tanimoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Maeda
authors.forename: Junichi
authors.initials: J
authors.lastname: Zaitsu
authors.forename: Takuro
authors.initials: T
authors.lastname: Hisanaga
authors.forename: Takuya
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Fujisawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Mizunaga
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yohei
authors.initials: Y
authors.lastname: Urata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Marumoto
authors.forename: Isao
authors.initials: I
authors.lastname: Hidaka
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Koji
authors.initials: K
authors.lastname: Aoyama
authors.forename: Masako
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: Taro
authors.initials: T
authors.lastname: Takami
authors.forename: Kaoru
authors.initials: K
authors.lastname: Omori
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Segawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Uchida
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamasaki
authors.forename: Kiwamu
authors.initials: K
authors.lastname: Okita
authors.forename: Isao
authors.initials: I
authors.lastname: Sakaida
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods / Q000639:trends*; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D004195:Disease Models, Animal; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology / Q000628:therapy*; D008113:Liver Neoplasms / Q000209:etiology; D008115:Liver Regeneration / Q000502:physiology; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods / Q000639:trends; D051379:Mice; D013156:Splenectomy
chemical_list: D016179:Granulocyte Colony-Stimulating Factor